Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al. used a cohort of more than 30,000 infected individuals with mild to moderate COVID-19 symptoms to determine the robustness and longevity of the anti–SARS-CoV-2 antibody response. They found that neutralizing antibody titers against the SARS-CoV-2 spike protein persisted for at least 5 months after infection. Although continued monitoring of this cohort will be needed to confirm the longevity and potency of this response, these preliminary results suggest that the chance of reinfection may be lower than is currently feared.
Science , this issue p. 1227
Article activity feed
-
SciScore for 10.1101/2020.07.14.20151126: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Studies were reviewed and approved by our institutional review board. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Participants were tested for SARS-CoV-2 antibodies and, if positive, obtained a titer level (1:80, 160, 320, 960 or ≥2880) using the Mount Sinai ELISA described here. SARS-CoV-2suggested: NoneDue to the lack of PCR testing in the New York area prior to mid-March, 2020, we also included people for antibody testing and screening if they were symptomatic with suspected SARS-CoV-2 symptoms after … SciScore for 10.1101/2020.07.14.20151126: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Studies were reviewed and approved by our institutional review board. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Participants were tested for SARS-CoV-2 antibodies and, if positive, obtained a titer level (1:80, 160, 320, 960 or ≥2880) using the Mount Sinai ELISA described here. SARS-CoV-2suggested: NoneDue to the lack of PCR testing in the New York area prior to mid-March, 2020, we also included people for antibody testing and screening if they were symptomatic with suspected SARS-CoV-2 symptoms after February 1, 2020, if they had a high risk exposure to someone with a positive SARS-CoV-2 PCR test, or were healthcare workers. mid-March, 2020suggested: NoneThe MSH-ELISA Anti IgG COVID-19 assay was also independently authorized as a laboratory developed test (LDT) for clinical application by the NYSDOH at the Mount Sinai Laboratory (MSL), Center for Clinical Laboratories, a division of the Department of Pathology, Molecular, and Cell-Based Medicine, New York, NY (CLIA# 33D1051889) from individuals suspected of previous COVID-19 infection by their healthcare provider, for the assessment of seroconversion from an antibody negative status to an antibody positive status in acutely infected patients, and for identification of individuals with SARS-Cov-2 IgG antibodies titers of up to 1:2880. Anti IgGsuggested: NoneSARS-Cov-2 IgGsuggested: NoneThe next day, cells were permeabilized and stained using an anti-NP antibody. anti-NPsuggested: NoneExperimental Models: Cell Lines Sentences Resources Vero.E6 cells (ATCC #CRL-1586) were seeded at a density of 20,000 cells per well in a 96-well cell culture plate (Corning, cat. no. 3595) one day before the assay was performed. Vero.E6suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)Software and Algorithms Sentences Resources Analysis was performed in GraphPad Prism. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-
SciScore for 10.1101/2020.07.14.20151126: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Studies were reviewed and approved by our institutional review board. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources However, due to the biological function of NP and the fact that it is shielded from antibodies by viral or cellular membranes, it is unlikely that NP antibodies can directly neutralize SARS-CoV-2. NPsuggested: NoneTherefore, the vast majority of positive individuals have moderate to high titers of anti-spike antibodies. … SciScore for 10.1101/2020.07.14.20151126: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Studies were reviewed and approved by our institutional review board. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources However, due to the biological function of NP and the fact that it is shielded from antibodies by viral or cellular membranes, it is unlikely that NP antibodies can directly neutralize SARS-CoV-2. NPsuggested: NoneTherefore, the vast majority of positive individuals have moderate to high titers of anti-spike antibodies. anti-spikesuggested: NoneBinding antibody titers tell us how robust the immune response to a certain virus or antigen is. antigen is.suggested: NoneCell Host Microbe 24, 221-233.e225 (2018). E. O. Saphire, S. L. Schendel, B. M. Gunn, J. C. Milligan, G. Alter, Antibody-mediated protection against Ebola virus. Antibody-mediated protection against Ebola virus .suggested: NoneParticipants were tested for SARS-CoV-2 antibodies and, if positive, obtained a titer level (1:80, 160, 320, 960 or ≥2880) using the Mount Sinai ELISA described here. SARS-CoV-2suggested: (Sino Biological Cat# 40143-R019, AB_2827973)Due to the lack of PCR testing in the New York area prior to mid-March, 2020, we also included people for antibody testing and screening if they were symptomatic with suspected SARS-CoV-2 symptoms after February 1, 2020, if they had a high risk exposure to someone with a positive SARS-CoV-2 PCR test, or were healthcare workers. mid-March , 2020suggested: NoneThe MSH-ELISA Anti IgG COVID-19 assay was also independently authorized as a laboratory developed test (LDT) for clinical application by the NYSDOH at the Mount Sinai Laboratory (MSL), Center for Clinical Laboratories, a division of the Department of Pathology, Molecular, and Cell-Based Medicine, New York, NY (CLIA# 33D1051889 ) from individuals suspected of previous COVID-19 infection by their healthcare provider, for the assessment of seroconversion from an antibody negative status to an antibody positive status in acutely infected patients, and for identification of individuals with SARS-Cov-2 IgG antibodies titers of up to 1:2880. Anti IgGsuggested: None<div style="margin-bottom:8px"> <div><b>SARS-Cov-2 IgG</b></div> <div>suggested: (Sino Biological Cat# 40588-R0004, <a href="https://scicrunch.org/resources/Any/search?q=AB_2857931">AB_2857931</a>)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Experimental Models: Cell Lines</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero.E6 cells (ATCC #CRL‐1586) were seeded at a density of 20,000 cells per well in a 96-well cell culture plate (Corning, cat. no. 3595) one day before the assay was performed.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div><b>Vero.E6</b></div> <div>suggested: JCRB Cat# JCRB1819, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_YQ49">CVCL_YQ49</a></div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Software and Algorithms</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analysis was performed in GraphPad Prism.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div><b>GraphPad Prism</b></div> <div>suggested: (GraphPad Prism, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002798">SCR_002798</a>)</div> </div> </td></tr></table>Data from additional tools added to each annotation on a weekly basis.
About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.
-
